17α-methylpregnenolone | 853-53-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17α-methylpregnenolone
• 英文别名: 3β-Hydroxy-17α-methyl-5-etienicsaeure；17-Methyl-20-oxo-pregnandienol-3β-on-(20)；17α-Methylpregnenolon；1-[(3S,10R,13S,17S)-3-hydroxy-10,13,17-trimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethanone
• CAS: 853-53-2；23137-48-6
• 化学式: C₂₂H₃₄O₂
• 分子量: 330.511
• InChiKey: KMBQCWJLPIEOTE-FGRFFZSTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• 3BÉTA-(BENZYLOXY)-17ALPHA-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS
  申请人：Aelis Farma

  公开号：EP3669876A1

  公开（公告）日：2020-06-24

  The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a cognitive disorders. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of cognitive disorders. Indeed, the compound of the invention is in vivo very potent in correcting the cognitive impairments observed in cognitive disorders.

  本发明一般涉及一种特定的孕酮衍生物，用于治疗认知障碍。 更具体地，本发明涉及一种式（I）的化合物 用于治疗认知障碍。 事实上，本发明的化合物在体内非常有效地纠正认知障碍中观察到的认知损伤。
• [EN] ANTAGONISTS OF CB1 RECEPTOR.<br/>[FR] ANTAGONISTES DU RÉCEPTEUR CB1
  申请人：INST NAT SANTE RECH MED

  公开号：WO2012160006A1

  公开（公告）日：2012-11-29

  The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.

  本发明涉及CB1受体拮抗剂，用于治疗以下病理状况或疾病的成员组：膀胱和胃肠道疾病；炎症性疾病；心血管疾病；肾病；青光眼；痉挛性疾病；癌症；骨质疏松；代谢性疾病；肥胖症；成瘾、依赖、滥用和复发相关疾病；精神和神经疾病；神经退行性疾病；自身免疫性肝炎和脑炎；疼痛；生殖系统疾病和皮肤炎性和纤维化疾病。
• 3-(4'-SUBSTITUTED)-BENZYL-ETHER DERIVATIVES OF PREGNENOLONE
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

  公开号：US20150284423A1

  公开（公告）日：2015-10-08

  The invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein R1 is C1-8 alkyl, C1-8 alkoxy, CN, NO 2 , amino, COOH, COOCH 3 , OH, N 3 , or halogen and R2 is H, OH, C1-8 alkyl, C1-8 alkoxy, C2-C6 alkenyl, halogen, Bn-O—, Bn- optionally substituted, or Ph- optionally substituted.

  本发明涉及化合物I式或其药学上可接受的盐：其中R1为C1-8烷基，C1-8烷氧基，CN，NO2，氨基，COOH，COOCH3，OH，N3或卤素，R2为H，OH，C1-8烷基，C1-8烷氧基，C2-C6烯基，卤素，Bn-O—，Bn-选择性取代，或Ph-选择性取代。
• Antagonists of CB1 receptor
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

  公开号：US10040816B2

  公开（公告）日：2018-08-07

  The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.

  本发明涉及一种 CB1 受体拮抗剂，用于治疗选自以下组别的病理状况或紊乱：膀胱和胃肠道疾病；炎症性疾病；心血管疾病；肾病；青光眼；痉挛；癌症；骨质疏松症；代谢紊乱；肥胖；成瘾、依赖、滥用和复发相关紊乱；精神和神经紊乱；神经退行性疾病；自身免疫性肝炎；骨质疏松症；代谢紊乱；肥胖；成瘾、依赖、滥用和复发相关疾病；精神和神经系统疾病；神经退行性疾病；自身免疫性肝炎和脑炎；疼痛；生殖系统疾病以及皮肤炎症和纤维化疾病。
• 3-(4′-substituted)-benzyl-ether derivatives of pregnenolone
  申请人：INSERM (Institut National de la Sante et de la Recherche Medicale)

  公开号：US10259839B2

  公开（公告）日：2019-04-16

  The invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein R1 is C1-8 alkyl, C1-8 alkoxy, CN, NO2, amino, COOH, COOCH3, OH, N3, or halogen and R2 is H, OH, C1-8 alkyl, C1-8 alkoxy, C2-C6 alkenyl, halogen, Bn-O—, Bn- optionally substituted, or Ph- optionally substituted.

  本发明涉及式（I）化合物或其药学上可接受的盐：其中 R1 是 C1-8 烷基、C1-8 烷氧基、CN、NO2、氨基、COOH、COOCH3、OH、N3 或卤素，R2 是 H、OH、C1-8 烷基、C1-8 烷氧基、C2-C6 烯基、卤素、Bn-O-、任选取代的 Bn-或任选取代的 Ph-。